Skip to content
ChickenStockChickenStock
ResearchAXSM
Axsome Therapeutics logo

Axsome Therapeutics (AXSM) stock

NASDAQ

$135.86-0.84%(-1.15)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-45.57x

Net loss — not comparable

P/B

68.57x

P/S

8.32x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 52.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 2, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

6 SEC filings
  • Jacobson Mark L.Chief Operating Officer · Sep 3, 2026Open-market sale10,000 shares · $2.1M
    Avg. price $208.650 shares held after
  • Jacobson Mark L.Chief Operating Officer · Sep 3, 2026Option exercise10,000 shares · $130K
    Avg. price $12.9510,000 shares held after
  • TABUTEAU HERRIOTChief Executive Officer · Aug 6, 2026Open-market sale4,660 shares · $997K
    Avg. price $213.957,229 shares held after
  • TABUTEAU HERRIOTChief Executive Officer · Aug 6, 2026Option exercise4,660 shares · $23K
    Avg. price $4.9511,889 shares held after
  • TABUTEAU HERRIOTChief Executive Officer · Aug 5, 2026Open-market sale45,004 shares · $9.5M
    Avg. price $212.017,229 shares held after
  • TABUTEAU HERRIOTChief Executive Officer · Aug 5, 2026Option exercise45,004 shares · $223K
    Avg. price $4.9552,233 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Axsome Therapeutics (AXSM) stock information

NASDAQ

Axsome Therapeutics (AXSM) is listed on NASDAQ. Its market capitalization is about $7.2B. On trailing-twelve-month earnings the P/E ratio is -45.57, and the P/B ratio is 68.57. Return on equity is -150.5%. These figures are computed in-house from official filings and are reference information only.

Axsome Therapeutics — frequently asked questions

What is the P/E ratio of Axsome Therapeutics (AXSM)?
On a trailing-twelve-month basis, AXSM trades at a P/E ratio of -45.57. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Axsome Therapeutics?
AXSM has a market capitalization of about $7.2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.